A subanalysis of the Bristol-Myers Squibb-funded APPRAISE study suggests medium-or high-level ultrasonography can determine whether patients treated with the company's rheumatoid arthritis medication abatacept have an early response.
The US Food and Drug Administration (FDA) has approved lesinurad (Zurampic; AstraZeneca Pharmaceuticals LP, Wilmington, DE) for use in combination with a xanthine oxidase inhibitor (XOI), which is approved for reducing the production of uric acid in the body, in patients with gout-associated hyperuricemia.
Q fever, caused by the bacterium Coxiella burnetii, is rare-approximately 40 cases are reported annually in the United States, and it occurs in <5% of patients with acute infection.
  • Bariatric Surgery Before Knee Arthroplasty
  • Adalimumab Proves Most Cost-Effective?
  • Online Reviews from Patients
  • Selective Uric Acid Reabsorption Inhibitor Approved
  • Challenging Step Therapy
Biosimilar tumor necrosis factor inhibitors (TNFis) were given the thumbs up in the European League Against Rheumatism (EULAR) 2015 update of its psoriatric arthritis (PsA) pharmacologic treatment recommendations.
Although fibromyalgia (FM) is better understood and recognized today than it was 25 years ago when FM classification criteria (ie, history of widespread pain, and pain on palpation of ≥11 of 18 specific sites) were first published, researchers still have an incomplete understanding of FM's mechanisms and predictors.
Page 2 of 2
Results 11 - 16 of 16
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology